Molecular cytogenic analysis of plasma cells in patients with multiple myeloma
Authors:
J. Balcárková 1; K. Procházková 1; V. Ščudla 2; M. Holzerová 1; J. Bačovský 2; M. Zemanová 2; H. Pospíšilová 1; J. Hanzlíková 1; J. Kropáčková 1; I. Prekopová 1; T. Pika 2; J. Minařík 2; K. Indrák 1; M. Jarošová 1
Authors‘ workplace:
Hemato-onkologická klinika FN a LF UP Olomouc
1; III. interní klinika FN a LF UP Olomouc
2
Published in:
Transfuze Hematol. dnes,13, 2007, No. 4, p. 176-182.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Multiple myeloma (MM) is a B-cell neoplasia characterized by the proliferation and accumulation of clonal plasma cells (myeloma cells) in bone marrow. Although the cause of the origin and development of MM are not well under-stood, genetic studies revealed that chromosomal aberrations play central role in pathogenesis and prognosis of patients with MM. We present the results of conventional cytogenetic and molecular cytogenetic analysis of 100 patients with MM. Using conventional cytogenetics chromosomal changes were detected in 23 (23 %) patients, in 8 patients complex karyotype was found. Using FICTION method cytogenetic changes were identified in 97 (97 %) patients. Deletion of RB1 gene was the most common aberration detected in 53 (53 %) patients, translocations involving IgH gene were identified in 25 (25 %) patients. The most common trisomy involved chromosomes 15 and 9. Cytogenetic and molecular cytogenetic analysis of 100 patient with MM confirmed high frequency of chromosomal abnormalities in advanced stages of the disease. Prognostic relevance of particular chromosomal abnormalities for overall survival cannot be evaluated due to short time of follow-up. In our study, the presence of complex karyotype was associated with a significantly shorter overall survival rate.
Key words:
multiple myeloma, FICTION, RB1 deletion, IgH rearrangement, trisomy
Sources
1. Kuehl M, Bergsagel PL. Multiple myeloma. Evolving genetic events and host interactions. Nature Reviews 2002; 2: 175–187.
2. Kyle AR, Therneau TM, Rajkumar V, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. NEJM 2002; 346: 564–569.
3. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromozomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood 2002; 99:2185–2191.
4. Debes-Marun CS, Dewald GW, Bryant S, et al. Chromozome abnormalities clustering and its implication for pathogenesis and prognosis in multiple myeloma. Leukemia 2003; 17: 427–36.
5. Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hematol 2002; 63: 276–300.
6. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101: 7–11.
7. Fonseca R, Bailey RJ, Ahman GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417–1424.
8. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–6338.
9. Fonseca R, Debes-Marun CS, Picken E. The recurrent IgH translocation associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.
10. Hideshima T, Bergsagel PL, Kuehl MW, Anderson KC. Advantages in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607–615.
11. Janssen JW, Vaandrager JW, Heuser T, et al. Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(1114)(q13q32). Blood 2000; 95: 2691–2698.
12. Shaugnessy Jr J, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromozomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98: 217–223.
13. Smadja NV, Bastard Ch, Brigaudeau Ch, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.
14. Fonseca R, Blood E, Rue M, et al. Clinical and biological implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.
15. Nilsson T, Hoglund M, Turesson I, et al. High frequencies of chromozomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromozomal preparation. Br J Haematol 2004; 126: 487–494.
16. Dewald G, Therneau T, Larson D, et al. Relationship of patients survival and chromozome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106: 3553–3558.
17. Jarosova M, Holzerova M, Mihal V, et al. Complex karyotypes in chidhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases. Cancer Genet Cytogenet 2003; 145: 161–168.
18. Shaffer LG, Tommerup N, Karger S. ISCN: An international system for human cytogenetic nomenclature. Basel 2005.
19. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromozome 13 abnormalities identified by FISH analysis and serum β2 microglobulin produce a powerful myeloma staging system for patients receiving high – dose therapy. Blood 2001; 97: 1566–15.
20. Finelli P, Fabris S, Zagano S, et al. Detection of t(414)(p16.3q32) chromozomal translocation in multiple myeloma by double color fluorescent in situ hybridization. Blood 1999; 94: 724–732.
21. Chesi M, Bergsagel PL Shonukan OO, et al. Frequent dysregulation of c-maf protooncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463.
22. Avet-Loiseau H, Daviet A, Saunier S, et al. Chromozome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000; 111: 116–1117.
23. Bergsagel P, Kuehl M, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303.
24. Wlodarska I, Matthews EV, Pospisilova H, et al. Telomeric IgH losses detectable by fluorescence in situ hybridization in chronic lymphocytic leukemia reflect somatic VH recombination events. J Mol Diagnostics 2007; 9: 47–54.
25. Nilsson T, Lenhoff S, Rylander L. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromozome segments as well as significant age- and sex-related differences. Br J Haematol 2003; 120: 960–969.
26. Ščudla V, Adam Z. pohled na diagnostiku a prognostické faktory u mnohočetného myelomu. Transfuze a hematologie dnes, 2005; 11(Suppl 2): 24–26.
27. Ščudla V, Pika T, Budíková M, Ordeltová M, Minařík J, Zemanová M, Bačovský J, Srovnalík K. Česká myelomová skupina. Příspěvek k hodnocení vztahu angiogenních cytokinů a vybraných biologických ukazatelů k prognostickým faktorům mnohočetného myelomu. Čas Lék čes 2006; 45: 929–935.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2007 Issue 4
Most read in this issue
- Steroid-refractory acute graft-versus-host disease (GVHD)
- Platelet tests – concise overview
- The impact of the various blood collection methods and the leukodepletion on the quality of the cryopreserved red blood cells
- Molecular cytogenic analysis of plasma cells in patients with multiple myeloma